ANAB at a glance
ANAPTYSBIO, INC (ANAB, SEC CIK 1370053) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on September 21, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ANAPTYSBIO, INC (ANAB) reported revenue of $234.6 million (up 157.0% from FY2024) and a net loss of $13.2 million. Diluted EPS was -$0.46.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding ANAPTYSBIO, INC (ANAB) shares worth $626.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by RENTON HOLLINGS on October 1, 2026 of 5,000 shares at $49.87 per share.
- In the last 90 days, ANAB insiders reported 0 open-market purchases ($0) and 1 open-market sale ($249K) on Form 4, a net sale of $249K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $234.6M
- +157.0% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$249K
- 13F holders
- 29 funds
- $626.0M · +3 vs prior quarter
- Latest 8-K
- Sep 21, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Business model: Biopharma company focusing on clinical development and commercialization collaborations, recognizing revenue mainly from milestones and royalties, not product sales
- New monetization deals in 2024: Sold additional Jemperli royalty receivables for $50M, expanding prior $250M monetization agreement with Sagard
- Strategic emphasis on Jemperli royalties, with increased milestone payments and royalty tiering under 2020 GSK Amendment
- Milestones recognized totaled $258M through 2025, including a $75M cash milestone for annual net sales exceeding $1 billion received in Dec 2025
- Accumulated deficit $772.6M as of Dec 31, 2025, with ongoing net losses expected due to clinical advancement and commercialization efforts
Risk Factors
- FDA acceptance of Vanda's imsidolimab BLA for GPP with target action date December 12, 2026, creating regulatory milestone risk
- Exposure to global macroeconomic shifts impacting 424-patient rosnilimab Phase 2b RA trial conducted worldwide
- Dependence on Vanda for commercialization and milestone payments from imsidolimab under exclusive license agreement
- Competition from approved immuno-oncology therapies like GSK's Jemperli with $1.1B sales in 2025, up >80% YoY
- Key-person risk and transition uncertainty from planned separation into two independent companies in Q2 2026
AI summary of the ANAB 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Risk Factors
- Newly triggered legal risk: Delaware Chancery Court litigation against Tesaro and GSK filed November 20, 2025
- Collaboration risk: GSK terminated the TIM-3 antagonist program in October 2025, eliminating future milestones and royalties
- Regulatory risk: Additional post-approval studies or trials could be required for Jemperli
- Market risk: Jemperli faces competition from Keytruda and other oncology therapies
- Revenue concentration risk: Royalties from Jemperli expected to comprise substantially all future revenues
AI summary of the ANAB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Results cover three months and transitional fiscal year ended June 30, 2026
- Press release issued September 21, 2026, with detailed financial results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Jemperli sales reached $644M for six months, up 34% year over year, strengthening Anaptys’ royalty-driven cash flow outlook
- Anaptys expects annualized Jemperli royalties above $390M by 2029 at GSK peak sales guidance above $2.7B
Item 5.07: Submission of Matters to a Vote of Security Holders
- Hollings Renton and John P. Schmid re-elected as Class III directors through the 2029 annual meeting
- KPMG LLP ratified as independent auditor for fiscal year ending June 30, 2027
Item 7.01: Regulation FD Disclosure
- Filing contains only the signature block for AnaptysBio’s July 30, 2026 8-K
- No substantive Regulation FD disclosure or investor-actionable information provided
AI summaries of ANAB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANAB
Don't miss the next ANAB filing
- Alerts as it files. A push when ANAB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANAB, by share count.
- Ask anything. An AI agent that reads every ANAB filing and answers with sources.
ANAB alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| RENTON HOLLINGS | Sell | Oct 1, 2026 | 5,000 | $49.87 |
| RENTON HOLLINGS | M | Oct 1, 2026 | 5,000 | - |
| RENTON HOLLINGS | M | Oct 1, 2026 | 5,000 | $18.03 |
| Orwin John A | M | Sep 15, 2026 | 1,300 | - |
| Orwin John A | M | Sep 15, 2026 | 1,300 | - |
| RENTON HOLLINGS | M | Jun 15, 2026 | 6,030 | - |
| Schmid John P. | M | Jun 15, 2026 | 6,030 | - |
| RENTON HOLLINGS | M | Jun 15, 2026 | 6,030 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $91.3M | $234.6M |
| Operating Income | - | -$114.9M | $47.9M |
| Net Income | -$163.6M | -$145.2M | -$13.2M |
| Op. Margin | - | -125.9% | 20.4% |
| Net Margin | - | -159.1% | -5.6% |
| Balance Sheet | |||
| Total Assets | $452.4M | $483.8M | $364.4M |
| Equity | - | $70.9M | $37.2M |
| ROE | - | -204.9% | -35.6% |
| Per Share | |||
| EPS | $-6.08 | $-5.12 | $-0.46 |
| Cash Flow | |||
| Operating CF | - | -$135.3M | $19.7M |
| CapEx | $807K | $358K | $87K |
Source: XBRL data in ANAPTYSBIO, INC (ANAB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ANAB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $626.0M |
| Q1 2026 | 26 | $491.5M |
| Q4 2025 | 22 | $408.5M |
| Q3 2025 | 23 | $293.3M |
| Q2 2025 | 23 | $247.9M |
| Q1 2025 | 21 | $150.9M |
| Q4 2024 | 17 | $108.0M |
| Q3 2024 | 16 | $123.5M |
- Millennium Management+331.7K (+70%)
- State Street Corp+293.7K (+30%)
- Goldman Sachs Group+251.3K (+76%)
- BlackRock+162.7K (+10%)
- Citadel Advisors LLC+160.9K (+69%)
- Morgan Stanley−736.8K (-74%)
- FMR LLC (Fidelity)−232.2K (-49%)
- Two Sigma Investments−202.1K (-43%)
- Bank of America Corp−83.3K (-17%)
- D.E. Shaw & Co−39.6K (-7%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANAB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 21, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 8-K | May 29, 2026 | - | Analysis | |
| 8-K | May 21, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 13, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 4 | Apr 29, 2026 | - | - | - |
| 8-K | Apr 24, 2026 | - | Analysis | - |
| 4 | Apr 23, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ANAB SEC filings: frequently asked questions
Are ANAB insiders buying or selling?
In the last 90 days, ANAPTYSBIO, INC (ANAB) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $249,372 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANAB stock?
As of June 30, 2026, the largest ANAPTYSBIO, INC (ANAB) holders among the 13F filers tracked by SignalX were BlackRock ($124.5 million), State Street Corp ($86.8 million), Vanguard Capital Management LLC ($61.2 million), Millennium Management ($54.5 million), Goldman Sachs Group ($39.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANAB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ANAPTYSBIO, INC (ANAB) reported revenue of $234.6 million (up 157.0% from FY2024) and a net loss of $13.2 million. Diluted EPS was -$0.46. The figures come from the XBRL data in the 10-K.
What are the main risks in ANAB's latest 10-K?
In the 10-K filed March 3, 2026, ANAPTYSBIO, INC (ANAB) flagged: FDA acceptance of Vanda's imsidolimab BLA for GPP with target action date December 12, 2026, creating regulatory milestone risk. Exposure to global macroeconomic shifts impacting 424-patient rosnilimab Phase 2b RA trial conducted worldwide. (AI summary of the Risk Factors section.)
What did ANAB report in its latest 8-K?
ANAPTYSBIO, INC (ANAB) filed an 8-K on September 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Results cover three months and transitional fiscal year ended June 30, 2026.
What are the latest ANAB SEC filings?
ANAPTYSBIO, INC (ANAB) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on May 12, 2026, an 8-K current report on September 21, 2026 and a Form 4 insider filing on October 2, 2026.
What is ANAB's SEC CIK number?
ANAPTYSBIO, INC (ANAB)'s SEC Central Index Key (CIK) is 1370053. EDGAR lists every ANAB filing under that number.
Ask anything about ANAB
The research agent reads ANAB's filings, financials, insider trades and 13F holders, then answers with sources.